EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

Severity of SARS-CoV-2 infection and the safety of COVID-19 vaccination in patients receiving HSCT

The coronavirus pandemic has put a great strain on worldwide healthcare systems. Patients with...

Fungal superinfections and COVID-19 in the ICU

The COVID-19 pandemic has caused a worldwide healthcare crisis. In addition to the morbidity caused by the initial infection, severely ill patients are...

When is it safe to schedule an allo-HSCT after COVID-19 infection?

During the virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the AML Hub spoke to...

How could new treatment combinations improve outcomes in TP53 mutant AML?

During the Society of Hematologic Oncology (SOHO) 2021 Annual Meeting, the AML Hub spoke to Naval Daver, MD Anderson Cancer...

Outcomes of decitabine and venetoclax treatment in mutant TP53 AML vs wild-type TP53 AML

TP53 is a tumor suppressor gene which protects cells against stress and is seen as the guardian of the genome...

Standardizing next-generation sequencing MRD assessment in AML

Detection of measurable residual disease (MRD) is recommended for the evaluation of treatment response in patients with acute myeloid...

Germline mutations in patients with hematologic malignancies

Germline mutations in patients with neoplasms are more common than expected and have been found not only in children but also adults with...

The efficacy and safety of ofatumumab plus prednisone in cGvHD

Improved understanding of the pathophysiology of chronic graft-versus-host disease (cGvHD) has led to new opportunities for frontline...

Venetoclax with intensive chemotherapy for younger patients with ND AML, or MDS

Intensive chemotherapy regimens have been the mainstay of newly diagnosed (ND) acute myeloid leukemia (AML) induction...

Post-transplant maintenance therapy: low dose decitabine + venetoclax is safe and effective for high-risk AML and MDS

Both acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) are...

The EHA Research Roadmap: Updates for malignant myeloid disorders

The European Hematology Association (EHA) previously published the EHA Research Roadmap in 2016, highlighting achievements in...

EPICOVIDEHA registry: Epidemiology and outcomes in patients with hematologic malignancies infected with COVID-19

Patients with hematologic malignancies (HMs) may have intensified immune dysregulation...

QUAZAR AML-001: Update from EHA2021 on survival outcomes according to NPM1 and FLT3 gene mutational status at diagnosis

Oral azacitidine (oral-AZA; CC-486) has been approved by both the U.S. Food and...

Sabatolimab for the treatment of poor prognosis myelodysplastic syndromes and acute myeloid leukemia

High-risk and very high-risk myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML) carry...

An overview of EHA guidelines for the use of antifungal prophylactic agents in acute myeloid leukemia

With increasing diversity of advances in the treatment of acute myeloid leukemia (AML), the need...